CJC-1295 and MK-677 (Ibutamoren) both increase growth hormone and IGF-1 levels, but through different receptor systems, different administration routes, and with different side effect profiles. CJC-1295 is an injectable GHRH analogue that stimulates pulsatile GH release from the pituitary. MK-677 is an oral ghrelin mimetic (technically not a peptide) that stimulates GH secretion through ghrelin receptor activation. The choice between them depends on administration preference, side effect tolerance, and desired pharmacological profile.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Both produce comparable body composition improvements over similar time periods. MK-677's continuous IGF-1 elevation and caloric intake increase (hunger) may produce slightly greater lean mass gain in those who can manage the caloric surplus productively. CJC-1295 + Ipamorelin suits body recomposition and fat loss phases better given its minimal hunger effect.
How Does CJC-1295 vs Work?
CJC-1295 (without DAC) binds the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and pulsatile release in a manner that mirrors natural GHRH. With its 30–45 minute half-life, each injection produces a distinct GH pulse that clears within hours — preserving physiological pulsatility. CJC-1295 with DAC extends this half-life to 6–8 days via albumin binding, producing more continuous GH elevation at the cost of pulsatility. CJC-1295 is almost always used with a GHRP (usually Ipamorelin) to amplify GH pulses through combined GHRH+GHRP receptor activation.
MK-677 activates the ghrelin receptor (GHS-R1a) — the same receptor targeted by GHRPs but through an orally bioavailable non-peptide mechanism. MK-677 has a 24-hour half-life (oral), producing sustained, relatively tonic GH and IGF-1 elevation throughout the day. This produces more continuous anabolic signalling but less physiological pulsatility. MK-677's ghrelin receptor activation also significantly increases appetite (ghrelin is the "hunger hormone") — a practical limitation in caloric deficit and a potential advantage for intentional bulking or conditions of appetite suppression.
Results: Body Composition and Recovery
Head-to-head comparison data is limited, but both produce similar endpoint effects over similar time periods: increased IGF-1, lean mass gain, improved recovery, and body composition improvements. MK-677's 24-hour IGF-1 elevation may produce modestly greater anabolic signal per day compared to the pulsatile profile of CJC-1295 without DAC, but this is offset by the greater hunger driving caloric intake upward. For body recomposition (simultaneous fat loss and muscle maintenance), the hunger effects of MK-677 are a practical challenge; CJC-1295 + Ipamorelin produces minimal hunger increase.
For sleep quality improvement — which both compounds affect through their nocturnal GH pulse enhancement — MK-677 at bedtime has a strong evidence base from clinical trials showing improved slow-wave sleep in both young and elderly subjects. CJC-1295 + Ipamorelin at bedtime also improves sleep quality through similar GH-dependent mechanisms. Both are effective; MK-677's once-nightly oral dosing makes compliance easier for sleep use cases.
What Are the Side Effects of CJC-1295 vs?
CJC-1295 + Ipamorelin: injection site reactions, water retention at higher doses (GH effect), mild increased hunger with Ipamorelin (less than GHRPs), potential for insulin sensitivity changes at high doses. No oral side effects. The most common reason to stop: injection discomfort or logistical challenges of injection-based administration.
MK-677: significant hunger increase (often the primary complaint), water retention (sometimes pronounced), lethargy in some users, and the same insulin sensitivity changes as any GH-elevating compound. Long-term use raises questions about sustained IGF-1 elevation. Notably, one arm of a long-term MK-677 clinical trial in elderly patients was stopped early due to increased adverse cardiac events — a concern for older individuals or those with cardiovascular risk factors.
CJC-1295 vs MK-677 Direct Comparison
| Factor | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Mechanism | GHRH receptor agonist | Ghrelin receptor agonist (oral) | — | — |
| Administration | SubQ injection | Oral — no injection needed | — | — |
| Half-life | 30–45 min (no DAC) | ~24 hours | — | — |
| GH pattern | Pulsatile (physiological) | Tonic/sustained | — | — |
| Hunger increase | Minimal (with Ipamorelin) | Significant | — | — |
| Water retention | Mild | Moderate to significant | — | — |
| WADA status | Prohibited | Prohibited (explicitly named) | — | — |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Both produce comparable body composition improvements over similar time periods. MK-677's continuous IGF-1 elevation and caloric intake increase (hunger) may produce slightly greater lean mass gain in those who can manage the caloric surplus productively. CJC-1295 + Ipamorelin suits body recomposition and fat loss phases better given its minimal hunger effect.
Yes — some researchers combine MK-677 with CJC-1295 to achieve both GHRH and ghrelin receptor stimulation simultaneously, similar to combining CJC-1295 with a GHRP. The combination should produce synergistic GH release. However, this significantly increases the caloric intake (from MK-677 hunger) and water retention effects. The combination is typically used in intentional muscle-building phases rather than recomposition.
Technically, MK-677 (Ibutamoren) is not a peptide — it is a non-peptide small molecule ghrelin mimetic. It is commonly grouped with research peptides because it acts through the same ghrelin receptor as peptide-based GHRPs and produces similar GH-secretagogue effects. It is orally bioavailable, which is its primary practical advantage over peptide-based alternatives.
MK-677 suits: those who cannot or will not inject, those using it specifically for sleep enhancement, and those in deliberate caloric surplus building phases who can use the hunger effect productively. CJC-1295 + Ipamorelin suits: those comfortable injecting, body recomposition goals, users sensitive to hunger side effects, and those preferring a more physiological pulsatile GH pattern.